Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 18 |
| Active Pipeline (Recruiting Now) | 8 (6) |
| Completed vs Stopped Early | 6 / 4 (22.2%) |
| Median Closed Actual Enrollment | 68 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 1 (1 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| The First Hospital of Jilin University | Changchun, Jilin | 4 |
| Peking University People's Hospital | Beijing, Beijing Municipality | 4 |
| Nanfang Hospital of Southern Medical University | Guangzhou, Guangdong | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04147208 | Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection | Phase II | COMPLETED |
| NCT03487107 | Phase 3 Study of Yimitasvir Phosphate Capsules | Phase III | COMPLETED |
| NCT05395416 | Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C | Phase II/III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Sunshine Lake Pharma Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.